Boryung Pharmaceutical and Kyowa Kirin Korea will be jointly selling 2 types of neutropenia treatments in Korea.

On the 2nd, Kyowa Kirin Korea and Boryung Pharmaceutical announced that the companies signed a co-promotion agreement to jointly sell the neutropenia treatments ‘Grasin (filgrastim)’ and ‘Neulasta (pegfilgrastim)’ in Korea.

Neutropenia treatments prevent cancer patients from developing the side effect of a weakened immune system due to decreased neutrophil levels when they receive anticancer therapies. Neutrophils are a type of white blood cell that fight infections from bacteria, etc.

Grasin and Neulasta are each 1st and 2nd generation neutropenia